ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2916

New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients

Alessandro Consolaro1,2, Chiara Trincianti1, Pieter van Dijkhuizen3, Giedre Januskeviciute4, Gabriella Giancane5, Alessandra Alongi1, Joost Swart3, Nicola Ruperto6,7 and Angelo Ravelli2,8, 1University of Genova, Genova, Italy, 2Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, 3UMC Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands, 4Istituto Giannina Gaslini, Genova, Italy, 5Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, 6Universita di Genova Pediatria II, Genova, Italy, 7Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 8University of Genova, Genoa, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, juvenile idiopathic arthritis (JIA), outcome measures and states of activation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in children with juvenile idiopathic arthritis (JIA). Cutoffs for the state of remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) are necessary to interpret the scores. Aiming to obtain cutoffs suitable for any clinical setting, new values were recently developed for JADAS10 and cJADAS10 in oligoarthritis and polyarthritis, based on a large multinational dataset (Consolaro A, et al. Arthritis Rheumatol. 2017;69s10). Aim of the study is to externally validate the new cutoffs for JADAS10 and cJADAS10 disease activity states.

Methods: Four JIA patients dataset were considered: 1) 4397 oligoarthritis and polyarthritis patients from the EPOCA study; 2) 148 oligoarthritis patients from the TRIMECA trial; 3) 172 polyarthritis patients from the Abatacept trial, 4) 113 patients first starting methotrexate from a monocentric retrospective cohort (Swart et al, Ann Rheum Dis. 2018;77:336-342). Face validity was assessed in dataset 1) by plotting the proportion of patients in remission and LDA against the values of the 6 parameters in the ACR JIA core set. Discriminative ability was assessed in datasets 2) and 3) by comparing the percentage of patients below the cutoff values in the different ACR pediatric categories of response. In dataset 1) we compared in each disease activity state, the level of pain (0-10 VAS), functional ability impairment, and number of restricted joints and the frequency of patients satisfied with disease outcome, starting a new medication for JIA, and having morning stiffness. Predictive ability was assessed in dataset 4) by calculating sensitivity and specificity of the cutoffs for remission and LDA after 3 months for treatment response after 12 months.

Results: Only most relevant results are described. JADAS10 and cJADAS10 cutoffs for remission allowed up to 1 active joint for polyarthritis and 0 for oligoarthritis. In dataset 2), 42% and 63% of patients achieving an ACRp70 response met the JADAS10 cutoffs for remission and LDA, respectively. In dataset 3), these percentages were 48% and 82%, respectively. In dataset 1), the median level of pain was 0, 1.5, 3, and 5.5 for polyarthritis patients in cJADAS10 remission, LDA, MDA, and HDA, respectively (Kruskal-Wallis p<0.001). The frequency of satisfaction with disease outcome was 94%, 76%, 56%, and 24% for oligoarthritis patients in cJADAS10 remission, LDA, MDA, and HDA, respectively (Chi2 test p <0.001). In dataset 4), 100% and 71% of patients with oligoarthritis classified as non-responders after 12 months had JADAS levels after 3 months above the cutoffs for remission and LDA, respectively. For polyarthritis, 90% and 80% of non-responders had JADAS levels after 3 months above the cutoffs for remission and LDA, respectively.

Conclusion: New JADAS cutoffs showed good face and content validity; achievement of remission and LDA defined by the cutoffs predicted the response to therapy. Cutoffs were developed and validated in a large multinational dataset and they are ready for use in clinical trials and routine practice.


Disclosure: A. Consolaro, None; C. Trincianti, None; P. van Dijkhuizen, None; G. Januskeviciute, None; G. Giancane, None; A. Alongi, None; J. Swart, None; N. Ruperto, full-time employee of the GASLINI Hospital, which has received contributions to support the research activities of the network of PRINTO from AbbVie Inc., AstraZeneca, Bristol-Myers Squibb, Janssen Biologics B.V., Eli Lilly and Co., “Francesco Angelini”,, 9,Astellas, AstraZeneca, Bristol-Myers Squibb, Italfarmaco, Janssen Biologics B.V., MedImmune, Roche, and Wyeth/Pfizer, 8; A. Ravelli, Abbvie, Bristol Myers Squibb, Novartis, Pfizer, Roche and Johnson & Johnson, 5, 8.

To cite this abstract in AMA style:

Consolaro A, Trincianti C, van Dijkhuizen P, Januskeviciute G, Giancane G, Alongi A, Swart J, Ruperto N, Ravelli A. New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/new-jadas10-and-cjadas10-based-cutoffs-for-juvenile-idiopathic-arthritis-disease-activity-states-validation-in-a-multinational-dataset-of-4830-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-jadas10-and-cjadas10-based-cutoffs-for-juvenile-idiopathic-arthritis-disease-activity-states-validation-in-a-multinational-dataset-of-4830-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology